LUGANO, Switzerland - The ESMO Targeted Anticancer Therapies Congress 2020 will take place from 2-4 March in Paris, France, where around four hundred stakeholders in the field of new drug development will meet. The Congress is designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies.
Expert panellists will discuss key aspects in the drug development field, such as the role of microbioma, looking at tools for its assessment as predictive factor to immunotherapy, its use to augment immunotherapy response and its role in patient selection for early phase clinical trials. Promoting a bench-to-bedside approach, the event will provide a comprehensive overview of the state of the art in the area of personalised medicine and molecular tumour boards, the identification of effective combination therapies in preclinical studies and the future of oncolytics, on top of reviewing best practice in the design of clinical trials.
The programme will also feature abstract-related sessions presenting recent advances in immunotherapy and individual epigenetics, metabolic and cell cycle targets.
Dr. Lillian Siu will be presented with the TAT 2020 Honorary Award for her pivotal contributions in the development of new anticancer drugs. She will deliver a keynote lecture entitled “Rear view mirror and crystal ball of oncology drug development”.
ESMO welcomes members of the press interested in reporting on cancer. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy. To register as press, please fill out the media registration form.
Further information: ESMO Press Office
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Targeted Anticancer Therapies Congress 2020
Official Congress Hashtag: #TAT20